Elanco Animal Health Incorporated Accounts Receivable, Allowance for Credit Loss, Current
Elanco Animal Health Incorporated (ELAN) had Accounts Receivable, Allowance for Credit Loss, Current of $17.00 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent · last filed 2026-02-24
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss, Current $17.00M.
- 2024-12-31: Accounts Receivable, Allowance for Credit Loss, Current $13.00M.
- 2023-12-31: Accounts Receivable, Allowance for Credit Loss, Current $18.00M.
- 2023-03-31: Accounts Receivable, Allowance for Credit Loss, Current $15.00M.
| Period end | Accounts Receivable, Allowance for Credit Loss, Current | Accounts Receivable, Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2025-12-31 | $17.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $13.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $18.00M 10-K · filed 2025-02-25 | |
| 2023-03-31 | $15.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $13.00M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $10.00M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $10.00M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $12.00M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $12.00M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $11.00M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $10.00M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $9.00M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $9.00M 10-K · filed 2022-02-28 | $8.50M 10-K · filed 2021-03-01 |
| 2020-09-30 | $8.80M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $7.30M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $7.40M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $6.20M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $6.30M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $5.70M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $8.30M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $8.40M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $8.80M 10-Q · filed 2018-11-08 | |
| 2017-12-31 | $9.80M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |